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ABSTRACT
Introduction Perinatal depression is common and can
often lead to adverse health outcomes for mother and
child. Multiple pharmacological and non-pharmacological
treatments have been evaluated against usual care or
placebo controls in meta-analyses for preventing and
treating perinatal depression compared. It is not yet
established which of these candidate treatments might be
the optimal approach for prevention or treatment.
Methods and analysis A systematic review and Bayesian
network meta-analyses will be conducted. Eight electronic
databases shall be searched for randomised controlled
trials that have evaluated the effectiveness of treatments
for prevention and/or treatment of perinatal depression.
Screening of articles shall be conducted by two reviewers
independently. One network meta-analysis shall evaluate
the effectiveness of interventions in preventing depression
during the perinatal period. A second network meta-
analysis shall compare the effectiveness of treatments for
depression symptoms in women with perinatal depression.
Bayesian 95% credible intervals shall be used to estimate
the pooled mean effect size of each treatment, and surface
under cumulative ranking area will be used to rank the
treatments’ effectiveness.
Ethics and dissemination We shall report our findings
so that healthcare providers can make informed decisions
on what might be the optimal approach for addressing
perinatal depression to prevent cases and improve
outcomes in those suffering from depression through
knowledge exchange workshops, international conference
presentations and journal article publications.
PROSPERO registration number CRD42020200081.
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INTRODUCTION
Background
Depression is the leading cause of disability
worldwide, it is a major contributor to the
global burden of disease, affecting a variety of
populations.1 Depression experienced during
pregnancy and after birth, also known as perinatal depression, is common and can affect
up to 20% of mothers.2 Previous systematic
reviews have shown that the prevalence of

Strengths and limitations of this study
►► This planned systematic review and network meta-

analysis shall evaluate all available evidence from
randomised controlled trials to evaluate the comparative effectiveness of each intervention.
►► This study shall be conducted following the latest
guidelines of the Cochrane Handbook for systematic
reviews of interventions.
►► Heterogeneity shall be assessed in the network
meta-analysis model within the direct-comparisons
model and comparing consistency between the direct and indirect model.
►► A limitation of this approach could be the different
contexts of managing perinatal depression across
studies in different regions and cultures.
►► To minimise the impact of this subgroup analysis
shall be conducted grouping studies by region, allowing for comparisons of interventions within different regions.

perinatal depression is generally higher in
low-to-middle-income countries than high-
income countries in both the antenatal and
postnatal stages.3 4 With perinatal mental
disorders, including depression, being more
prevalent in mothers who are the most socioeconomically disadvantaged.4 Cultural factors
also have been indicated to be sources of
inequality for perinatal mental illness, these
include cultural gender-
bias, gender-
biased
violence; both physically and mentally.4
Perinatal depression can cause a range
of adverse health outcomes for women and
the development of their children. Depression during pregnancy can lead to multiple
problems, including premature delivery,
gastrointestinal pain, poorer self-
report
health and functioning, it can also lead to an
increased risk of smoking or alcohol abuse.5 6
Longer-term depression beyond 1-year post
partum, can lead to later problems during
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Rationale
analysis facilitates all
Using a Bayesian network meta-
interventions to be compared equally with one-another
by using the direct evidence (within study comparisons
of treatments) and indirect evidence (comparing treatments across different studies), which previous systematic
review studies and clinical guidelines in perinatal depression have not yet explored. This approach can provide
evidence for the relative comparative effectiveness of each
treatment and potentially identify the optimal approach
for preventing cases and treating symptoms of perinatal
depression.
We will conduct a comprehensive systematic review
of available peer-reviewed published trial studies for all
pharmacological and non-
pharmacological interventions, addressing perinatal depression by conducting a
network meta-analysis. Based on this we will be able to
compare each treatments’ effectiveness with one-another
and recommend types of interventions that may optimally address the prevention and treatment of perinatal
depression. An example of this could be making relative
comparisons on the effectiveness of interventions that
require fewer resources for health providers to implement that is scalable against more resource intensive
interventions that require trained specialists or equipment to implement and the level of trade-off in clinical effectiveness between those interventions. Another
advantage of Bayesian network meta-analysis is statistical
certainty can be estimated, this allows for identifying
potentially promising interventions with low levels of
statistical certainty that may require further investigation
to establish effectiveness.
Objectives
This study will assess the clinical benefits of different
interventions for addressing the prevention and treatment of perinatal depression. Two objectives have been
developed for this study.
1. To identify the optimal approach for preventing perinatal depression in women.
2. To identify the optimal approach for the treatment of
perinatal depression in women.
METHODS
The protocol of this study has been developed following
the Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols guidelines (online supplemental
appendix 1) and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) extension statement on the reporting of systematic reviews that
incorporate network meta-analysis of healthcare interventions.30 31
Eligibility criteria
Study selection and eligibility criteria were based on the
Population, Intervention, Comparison, Outcome, Study
design (PICOS)-related to objectives 1 and 2 (table 1).
Briefly, studies on participants who are perinatal women
Smith RD, et al. BMJ Open 2021;11:e048764. doi:10.1136/bmjopen-2021-048764
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parenting, including lower interaction and sensitivity
between mother and infant. Long lasting depression has
been shown to lead to further difficulties in later years
for the offspring, including emotional and behavioural
difficulties.7–9 Successful prevention of postnatal depression occurring can be achieved. Identifying those with
depression early; either during the antenatal period
(during pregnancy) or in the postnatal period (up to
1-year post partum) provides a critical opportunity for
earlier treatments and prevents poorer outcomes from
occurring.10 11
Despite its significant burden on maternal and child
health, less than half of pregnant women suffering from
depression are identified within healthcare.12 Attitudes
towards identifying cases of perinatal depression among
clinicians are positive. Still, there is a need for support
strategies that can identify and treat those at risk of perinatal depression within routine practice.13 A systematic
review suggested that the Whooley questions, a set of two-
item yes/no answered questions were a valid and feasible
approach for identifying possible positive cases of perinatal depression.14
Once identified, healthcare services can provide interventions for preventing those at risk of depression occurring in the future or offering treatments for those with
depression. There is a wide variety of interventions that
are shown to be effective in treating depression symptoms in perinatal women compared with non-
active
controls: psychological interventions, pharmacological
interventions or combinations of both15; psychoeducation or parenting education16; psychosocial interventions
for treatment and prevention17–20; systemically oriented
psychotherapies21; mindfulness22; family therapy23; physical activity24 and yoga-based interventions.25 In later stage
postnatal women, meta-analyses have suggested cognitive
behavioural therapy, interpersonal therapy, counselling
and other psychological interventions are effective in
treating depression symptoms when compared with usual
care.26 Another meta-analysis on antidepressants for postnatal depression in a small number of studies show that
selective serotonin reuptake inhibitors are effective for
depression compared with placebo.27
Clinical guidelines recommend screening and treatment for perinatal depression, these guidelines do not
provide recommendations on which treatments are most
effective.28 Treatment options for depression during
pregnancy may vary depending on different severities
of depression.10 Many treatments previously evaluated
were identified as effective on depression symptoms
compared with usual care or placebo, but the relative
comparability of these treatments has not previously
been investigated.26 29 Relative comparisons of different
treatments would allow healthcare providers to make
informed decisions on how different active treatments
can be compared. The relative comparison of treatments
could also provide evidence for the optimal approach
to treating perinatal depression based on all available
evidence.

Open access

Objective 1
Population

Perinatal mothers, or if not identified as perinatal within the study; females between 20th week of gestation to 1 year
after birth, no limitation of setting, excluding those currently experiencing a depression episode

Intervention

Interventions that aimed to prevent perinatal depression including pharmacological and non-pharmacological
interventions, interventions were not limited for setting

Comparison

Studies will not be limited for comparisons groups, and shall include other active interventions or non-active controls

Outcome

Depression diagnosis (determined through the clinical interview)

Study design

Randomised controlled trials only

Objective 2

 

Population

Perinatal mothers, or if not identified as perinatal within the study; females between 20th week of gestation to 1 year
after birth, no limitation of setting, diagnosed or known to be currently experiencing a depression episode

Intervention

Interventions that aimed to treat perinatal depression symptoms including pharmacological and non-pharmacological
interventions, interventions were not limited for setting

Comparison

Studies will not be limited for comparisons groups including other active interventions or non-active controls

Outcome

Measurements of depression severity or symptoms

Study design

Randomised controlled trials only

between 20 weeks gestation to 1 year after birth will be
included. We selected 1 year after birth to reflect the time
period in which there is a risk of postpartum depression
occurring between day 1 to 1-year post partum.32 We did
not specify any limitations on interventions as this review
aims to identify and evaluate all intervention types that
address depression within the target population. Given
the advantages of the network meta-analysis approach,
no limitations will be placed on the comparison group
for studies. Outcomes for objective 1 will be: confirmed
cases of depression and for objective 2: measurements of
depression severity or symptoms. Study design will only
include randomised controlled trials to minimise the risk
of bias when comparing effectiveness of interventions.
Eligibility is displayed in table 2. Studies that include
participants with substance abuse, psychotic or developmental disorders or medical conditions, long-term care,
residential facilities or those in institutions (psychiatric
inpatients) were excluded as the treatment needs of
these populations’ depression symptoms differ compared
with those with depression alone.33 Included articles were
limited to those written in English, there was no limitation of publication year for included articles.
Sources of information
Databases searched electronically will be MEDLINE,
British Nursing Index (BNI), EMBASE, Cumulative

Index to Nursing and Allied Health (CINAHL Plus),
PsycINFO, Cochrane Central Register of Controlled Trials
(CENTRAL), Cochrane Database of Systematic Reviews
and Web of Science (WoS). We selected MEDLINE,
EMBASE and WoS databases based on recommendations
for Cochrane Handbook covering major health sciences
topics. We also selected specialist subject databases BNI,
CINAHL Plus and PsycINFO based on their relevance to
the study objectives. WHO’s trials portal and clinicaltrials.
gov will be searched to identify unpublished studies or
studies still ongoing.
We shall conduct searches of reference lists and forward
citation of identified and included studies using the
Web of Science database for additional papers. We shall
exclude studies that are published systematic review or
literature review identified during our electronic searches
but shall examine the reference lists for additional candidate studies.
Search strategy
Searches of online databases will commence in August
2021. The search strategy has been developed based on
the two sets of PICOS with one for each review question.
We identified all search terms, related to the two sets of
PICOS, from previously published meta-analyses on the
prevention or treatment of perinatal depression15–25 to
maximise sensitivity of our search strategy in identifying

Table 2 Inclusion and exclusion criteria for study selection
Inclusion criteria

Exclusion criteria

►► Research paper in a peer-reviewed journal
►► Studies that met the PICOS criteria for either

►► Populations that include persons with substance abuse, psychotic

objectives 1 or 2

or developmental disorders or medical conditions, in long-term care,
residential facilitates or those in institutions (psychiatric inpatients),
studies that include subsets these populations were excluded if they
exceeded 50% of the study sample
►► Study designs other than randomised controlled trials

Smith RD, et al. BMJ Open 2021;11:e048764. doi:10.1136/bmjopen-2021-048764
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Table 1 PICOS for search strategy and study selection criteria
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Data management
Studies retrieved in our search strategy shall be downloaded and stored in EndNote (X9) where duplicates
across different sources will be removed.
Study selection process
Screening of studies shall be conducted using the inclusion and exclusion criteria (table 2). Two reviewers (RDS,
JG, SCH or HLI) shall conduct study selection, with both
reviewers reviewing each retrieved study independently.
Differences in assessment or any disagreements over the
eligibility of studies were resolved by discussion, and in
cases of disagreement, the third reviewer (KY-WL) would
be consulted. Screening of studies shall be conducted in
two different stages: (1) title and abstract, where studies
will only be excluded if there is a clear disparity to eligibility criteria, if it is unclear, then articles or included articles will be further screened in the stage; (2) full article
screening, where eligibility can be decided based on all
reported article information, including supplementary
materials. The rationale for the exclusion of studies will
be recorded. Piloting of the data selection process shall
take place prior to the full study selection, with 100 articles randomly selected from the search retrieved. Adjustments to the inclusion and exclusion criteria and study
selection process may be made following piloting.
Data extraction
Data extraction shall be conducted by two of the
reviewers (RDS, JG, SCH or HLI) independently using
a standardised extraction form. Differences in assessment or any disagreements for data extraction of studies
will be resolved by discussion, and in cases of disagreement, the third reviewer (KY-WL) will be consulted. The
data extraction forms were taken from the Cochrane
Consumers and Communication Review Group’s Data
Extraction Template for Cochrane Reviews, and were
modified to fit this systematic review. The extracted
information will include study setting, study participant
demographics and baseline characteristics, details of
the intervention and control conditions, study methodology, recruitment and study completion rates, outcomes
and times of measurement, indicators of acceptability to
users, suggested mechanisms of intervention action and
information for the assessment of the risk of bias. Missing
data will be requested from study authors.
Risk of bias assessment
Risk of bias will be assessed using version 2 of the Cochrane
Risk of Bias tool (RoB2).34 This tool includes five-domains
based on the risk of biases within the randomisation
process, deviation from intervention design, missing
outcome data, measurement of outcome and reporting
of results. The risk of bias assessment shall be completed
4

following the guidance released with the RoB2. Possible
risk of bias judgments shall include (1) low risk, (2) some
concerns and (3) high risk of bias. Results of the risk of
bias shall be presented within each domain of risk of bias,
as well as an overall score for each study. Overall risk of
bias shall be judged based on the suggested criteria of
the RoB2 guidance document. Piloting and adaption of
the wording in the risk of bias assessment, if necessary,
shall be conducted prior to the full review. Risk of bias
will be evaluated by two of the reviewers (RDS, JG, SCH
or HLI) independently evaluate the risk of bias. Differences in assessment or any disagreements will be resolved
by discussion, and in cases of disagreement, the third
reviewer (KY-WL) will be consulted.
Data analysis
Effect measurements
Data from each study shall be extracted with effect size
calculated. For studies addressing review question 1,
follow-
up data on the number of positive depressions
cases in each arm shall be extracted allowing for relative
risk (RR) to be calculated in each arms’ comparison, with
RR of less than 1 representing reduced risk of depression.
For review question 2, treatment effect shall be calculated
using mean difference (MD) if possible, or standardised
MD (SMD) for depression severity. To calculate SMD;
difference in changes (from baseline to follow-up) for
intervention arms shall be used, divided by the pooled SD
of change. For studies with three or more arms, a reference group shall be taken to calculate the SMD. Studies
with negative SMD effect sizes representing improvements in reducing depression severity. Score changes
will be used to control for possible baseline differences
between study arms. For studies with multiple follow-up
time points, we shall use the longest duration, up to a
maximum of 1 year from the end of the intervention.
In studies using median and IQRs we shall impute these
following the Cochrane Handbook.35 Studies that do not
report the SD of change from baseline will be imputed
following the Cochrane Handbook. A correlation coefficient for imputation of SD of change shall be estimated
based on the mean correlation in studies that do report
all relevant data. If no studies report baseline, follow-up
and change values, we shall take the conservative value
of r=0.5 to estimate SD of change. Where possible, we
shall use the intention to treat sample for analyses. Interventions will be grouped for the network analysis using
categories used by previous individual meta-analysis16–25
as a framework, new emerging interventions not previously evaluated in meta-analysis shall be organised and
grouped by agreement with the reviewing team.
Network meta-analysis implementation
Two network meta-analyses shall be conducted for depression prevention, using RR and treatment of depression
severity, using SMD. We shall estimate model consistency
by comparing the RR or SMD of the direct (within study
comparisons) and indirect comparisons (between study
Smith RD, et al. BMJ Open 2021;11:e048764. doi:10.1136/bmjopen-2021-048764
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all definitions of perinatal depression and minimise risk
to missing relevant studies. An example full list of search
terms for the MEDLINE database can be found in online
supplemental appendix 2.

Open access

Patient involvement
Patients and the public were not involved in the design of
the protocol or analysis of this study.
Ethics and dissemination
Ethics is not required for this study, given that this is a
protocol for a systematic review, which uses published
data. The results of the review would be widely disseminated locally, nationally, and internationally. A paper
would be submitted to a leading peer-
review journal
in this field, reporting of the study will adhere to the
PRISMA extension statement on the reporting systematic reviews that incorporate network meta-
analysis of
Smith RD, et al. BMJ Open 2021;11:e048764. doi:10.1136/bmjopen-2021-048764

healthcare interventions.31 When presenting our findings
from this study, the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) scoring
for evidence and strength of recommendations shall be
made following the criteria in the GRADE handbook.38
The findings shall also be presented at a relevant international conference.
Twitter Claire Anna Wilson @drclairewilson
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